Build or Buy? A Guide to Biometrics Resourcing
Build or Buy? A Guide to Biometrics Resourcing
The Strategic Crossroads Every Biotech and Pharma Company FacesIn today's increasingly complex market, where 80% of clinical trials face delays and competition is intensifying, the question isn't whether you need robust biometrics capabilities—it's whether you should build them in-house or partner w...
Checklist: How to Select a Biometrics Partner
Checklist: How to Select a Biometrics Partner
Choosing the right biometrics partner is a critical decision that can significantly impact your clinical development timeline, budget, and ultimate regulatory success. This comprehensive checklist will guide you through the essential criteria to evaluate potential biometrics partners and help you ma...
Top 5 Biometrics Mistakes That Delay Clinical Trials
Top 5 Biometrics Mistakes That Delay Clinical Trials
In today's complex clinical development landscape, where trial costs continue to rise and timelines stretch ever longer, biometrics excellence has become a critical success factor. Yet even experienced organizations repeatedly fall victim to common biometrics pitfalls that silently derail timelines ...
SDTM、ADaM or Define.XML: The Three Pillars of Data Standardization in Drug Development
SDTM、ADaM or Define.XML: The Three Pillars of Data Standardization in Drug Development
IntroductionIn drug development and clinical research, data standardization is the cornerstone of ensuring reproducible results, traceability, and compliance with regulatory review requirements. SDTM (Study Data Tabulation Model), ADaM (Analysis Data Model), and Define.XML—defined by CDISC (Clinical...